Get the Stockscreener App
21.18
0.81%
0.31
Dyne Therapeutics Inc stock is traded at $21.18, with a volume of 556.20K.
It is up +0.81% in the last 24 hours and up +21.13% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$20.87
Open:
$20.435
24h Volume:
556.20K
Relative Volume:
0.32
Market Cap:
$3.49B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-6.5652
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+16.43%
1M Performance:
+21.13%
6M Performance:
+3.09%
1Y Performance:
+107.08%
1-Day Range:
$20.43
$21.54
1-Week Range:
$18.24
$21.54
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
21.11 | 3.27B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
467.75 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
619.55 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
923.26 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.32 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
170.44 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics appoints Barry Greene to board of directors By Investing.com - Investing.com South Africa
Dyne Therapeutics Appoints Barry Greene to Board of Directors - Investing News Network
Dyne Therapeutics appoints Barry Greene to board of directors - Investing.com
Dyne Therapeutics elects Barry E. Greene to Board as Class I director - TradingView
Barry Greene joins Dyne Therapeutics (DYN) board with new option grant - Stock Titan
Entity tied to Dyne (DYN) director sells 84K pre-planned shares - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 18, 2026 - marketscreener.com
Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne awards stock options, RSUs to 6 newly hired employees - Stock Titan
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics Inc (DYN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. - Investing News Network
Dyne therapeutics CEO John Cox sells $49,179 in stock - Investing.com UK
Dyne therapeutics CEO John Cox sells $49,179 in stock By Investing.com - Investing.com UK
Dyne Therapeutics (DYN) CMO auto-sells shares to cover tax withholding - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU tax withholding - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CEO logs automatic RSU tax sale - Stock Titan
ForDyne B.V. (DYN) reports multiple April 2026 resale lots totaling millions - Stock Titan
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million - citybiz
Dyne Therapeutics Shares Rise After Amendment to Debt Facility - marketscreener.com
Dyne Therapeutics, Inc. 8-K SEC Filing: Company Details, Stock Info, and Regulatory Compliance (June 2026) - Minichart
Dyne Therapeutics Expands Loan Facility to $400 Million with Hercules Capital Amendment - marketscreener.com
Dyne Therapeutics amends loan facility, secures $50 million By Investing.com - Investing.com South Africa
Dyne Therapeutics amends loan agreement to expand debt facility to $400 million - Investing.com UK
Dyne Therapeutics amends loan facility, secures $50 million - Investing.com
Dyne Therapeutics Expands Hercules Loan Facility to $400 Million, Draws $50 Million Tranche - TradingView
Dyne Therapeutics Secures Up to $125 Million in Additional Borrowing Capacity for Clinical Advancements - Quiver Quantitative
Dyne Therapeutics (NASDAQ: DYN) boosts Hercules loan capacity to $400M - Stock Titan
Dyne Secures $400M War Chest to Push Rare Disease Drugs to Market - BriefGlance
Dyne Therapeutics Secures $125 Million in Additional Financing - Intellectia AI
DYN (Nasdaq: DYN) affiliate sale of 3,311 shares; 9,081 RSUs listed - Stock Titan
Why Dyne Therapeutics (DYN) Is Up 11.4% After Completing ACHIEVE Cohort Enrollment And Expanding Share Count - Sahm
Trading Systems Reacting to (DYN) Volatility - Stock Traders Daily
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kersten Dirk | Director |
Jun 17 '26 |
Sale |
20.14 |
37,454 |
754,316 |
4,159,119 |
| Kerr Douglas | Chief Medical Officer |
Jun 16 '26 |
Sale |
18.33 |
887 |
16,259 |
169,155 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Jun 16 '26 |
Sale |
18.33 |
145 |
2,658 |
154,208 |
| Cox John | CEO & President |
Jun 16 '26 |
Sale |
18.33 |
2,683 |
49,179 |
368,151 |
1.21%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):